No Data
Beijing Aosaikang Pharmaceutical (002755): Profit increased compared to the previous period, early molecules have BIC potential.
Event description: On October 31, 2024, beijing aosaikang pharmaceutical released the 2024 third quarter report: For the first three quarters of 2024, revenue reached 1.38 billion yuan, a year-on-year increase of 23.6%; the profit attributable to shareholders of the listed company was
Osecon: Report for the third quarter of 2024
Beijing Aosaikang Pharmaceutical (002755.SZ) net income in the third quarter increased by 296.25% year-on-year.
Galaxy10 reported on October 30th that Beijing Aosaikang Pharmaceutical (002755.SZ) released its third-quarter report. The company achieved revenue of 1.384 billion yuan in the first three quarters, a year-on-year increase of 23.64%; net income of 0.127 billion yuan, a year-on-year increase of 168.79%. In the third quarter alone, revenue reached 0.462 billion yuan, a year-on-year increase of 13.23%; net income was 51.4232 million yuan, a year-on-year increase of 296.25%.
Express News | Beijing Aosaikang Pharmaceutical: Subsidiary Nalatrexone Malate Tablets Obtained Pharmaceutical Registration Certificate
Express News | Beijing Aosaikang Pharmaceutical: plans to increase capital to AskGene by 0.22 billion yuan
Hong Kong stocks anomaly | Innovent Bio (01801) fell another 10% during the day, reaching a strategic cooperation with Beijing Aosaikang Pharmaceutical, the founder recently reduced holdings by over 0.15 billion Hong Kong dollars of stocks
Innovent Bio (01801) fell by another 10% during the day, as of the time of publication, a decrease of 4.92%, closing at HKD 47.35, with a turnover of 1.627 billion Hong Kong dollars.
No Data
No Data